The PBAC has recommended the listing of a second biosimilar to infliximab (Remicade). A year after Pfizer’s biosimilar (Inflectra) gained PBS listing MSD’s biosimilar Renflexis is now recommended by the PBAC on a cost minimisation basis with infliximab (Remicade) for all indications – rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, chronic plaque psoriasis, Crohn’s disease, fistulating ...
Second infliximab biosimilar on its way
By Nicola Garrett
14 Feb 2017